What is Jardiance (empagliflozin)?
- Jardiance is an oral medication used to improve glycemia (blood glucose) control in patients with type 2 diabetes. Jardiance is a sodium-glucose cotransporter (SGLT2) inhibitor. It is similar to canagliflozin (Invokana) and dapagliflozin (Farxiga).
What brand names are available for empagliflozin?
Jardiance is the brand name available for empagliflozin in the US.
Is Jardiance (empagliflozin) available as a generic drug?
No
Do I need a prescription for Jardiance (empagliflozin)?
Yes
What are the uses for Jardiance (empagliflozin)?
- Jardiance is used with
diet and
exercise to control blood glucose in adults with
type 2 diabetes. - Jardiance also is used to reduce the risk of cardiovascular death (for example, death from
heart attacks) in adults with
type 2 diabetes and
cardiovascular disease.
What are the side effects of Jardiance (empagliflozin)?
The most common side effects of Jardiance are:
- Urinary tract infections
- Female genital fungal infections
- Upper respiratory tract infection
- Increased cholesterol
- Joint pain
- Nausea
- Increased creatinine
- Increased urination
Other possible side effects of Jardiance include:
Volume depletion and associated conditions, which include:
Serious side effects of Jardiance include:
- Hypotension
- Kidney failure
- Ketoacidosis
- Kidney infections (pyelonephritis)
- Hypoglycemia (when combined with insulin or sulfonylureas)
What is the dosage for Jardiance (empagliflozin)?
- The recommended dose of Jardiance is 10 mg once daily. It should be taken in the morning with or without food. The dose may be increased to 25 mg daily based on patient tolerance and blood glucose levels.
- Patients with volume depletion should be treated for their depletion before receiving
Jardiance. - Jardiance should not be used by patients whose glomerular filtration rate (a measure of kidney function) is 45 mL/min/1.73 m2
Latest Diabetes News
- COVID Antiviral Pill Approval
- Are Diet Drinks Any Better?
- Diabetes Ups Alzheimer’s Risk
- Key Protein in TBI Patients
- Breastfeeding Helps Postpartum Depression
More Health News »
Trending on MedicineNet
- Breast Cancer Warning Signs
- CMT Disease
- Main Cause of Graves’ Disease
- RSV in Adults
- Ehlers-Danlos Syndrome
Which drugs or supplements interact with Jardiance (empagliflozin)?
- Combining Jardiance with diuretics increases the frequency of urination and volume of urine produced. This may increase the risk of
dehydration. - Combining Jardiance with insulin or
drugs that increase insulin secretion increases the risk for hypoglycemia. - Jardiance and other
SGLT2 inhibitors increase excretion of glucose in urine and will cause positive urine glucose tests. Therefore, monitoring glucose control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors. Alternative tests should be used to monitor glucose control.
QUESTION
______________ is another term for type 2 diabetes.
See Answer
Is Jardiance (empagliflozin) safe to use during pregnancy or while breastfeeding?
- Use of Jardiance has not been adequately evaluated in
pregnant women. In animal studies,
Jardiance affected renal (kidney) development and maturation in rats.
Jardiance is not recommended during the second and third
trimesters of
pregnancy. - It is not known whether Jardiance is excreted in human
breast milk. However,
Jardiance is secreted in the milk of lactating rats, and exposure damages the developing kidneys in the rat fetus. Currently, the manufacturer does not recommend use of
Jardiance while nursing.
What else should I know about Jardiance (empagliflozin)?
What preparations of Jardiance (empagliflozin) are available?
- Tablets: 10, 25 mg
How should I keep Jardiance (empagliflozin) stored?
- Store empagliflozin at room temperature, between 15 C and 30 C (59 F and 86 F).
How does Jardiance (empagliflozin) work?
- SGLT2 is found in the kidney tubules and is responsible for reabsorbing the majority of glucose filtered out of the blood by the kidneys. By inhibiting SGLT2 empagliflozin reduces the reabsorption of filtered glucose and consequently increases excretion of glucose in the urine. Empagliflozin is not recommended for use in patients with moderate to severe
kidney disease.
When was Jardiance (empagliflozin) approved by the FDA?
- Empagliflozin was approved by the US FDA in August 2014.